Drug Profile
Research programme: erythropoietin oral - HanAll Biopharma
Alternative Names: EPO agent - HanAll Biopharma; HL033Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Nautilus Biotech
- Developer HanAll Biopharma
- Class Erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Anaemia; Renal failure
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anaemia in South Korea (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Renal-failure in South Korea (PO)
- 21 Sep 2010 Research programme: erythropoietin oral - HanAll Pharmaceutical is available for licensing www.hanallbiopharma.com